Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription.

Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L.

Genes Dev. 2006 May 1;20(9):1075-80.

2.

Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins.

Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I.

Mol Biol Cell. 2005 Oct;16(10):4623-35.

3.

Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly.

Rose G, Dato S, Altomare K, Bellizzi D, Garasto S, Greco V, Passarino G, Feraco E, Mari V, Barbi C, BonaFe M, Franceschi C, Tan Q, Boiko S, Yashin AI, De Benedictis G.

Exp Gerontol. 2003 Oct;38(10):1065-70.

PMID:
14580859
4.

Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene.

Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, Watanabe T, Ohama E, Tahimic CG, Kurimasa A, Oshimura M.

Biochem Biophys Res Commun. 2003 Sep 26;309(3):558-66.

PMID:
12963026
5.

Dolly, no longer the exception: telomeres and implications for transplantation.

Shiels PG, Jardine AG.

Cloning Stem Cells. 2003;5(2):157-60. No abstract available.

PMID:
12930628
6.

Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle.

Dryden SC, Nahhas FA, Nowak JE, Goustin AS, Tainsky MA.

Mol Cell Biol. 2003 May;23(9):3173-85.

7.

The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase.

North BJ, Marshall BL, Borra MT, Denu JM, Verdin E.

Mol Cell. 2003 Feb;11(2):437-44.

8.

TP53 and breast cancer.

Børresen-Dale AL.

Hum Mutat. 2003 Mar;21(3):292-300. Review.

PMID:
12619115
9.

"SIRT8" expressed in thyroid cancer is actually SIRT7.

Frye R.

Br J Cancer. 2002 Dec 2;87(12):1479. No abstract available.

10.

SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria.

Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13653-8.

11.

Senescence and epigenetic dysregulation in cancer.

Neumeister P, Albanese C, Balent B, Greally J, Pestell RG.

Int J Biochem Cell Biol. 2002 Nov;34(11):1475-90. Review.

PMID:
12200040
12.

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.

Johnstone RW.

Nat Rev Drug Discov. 2002 Apr;1(4):287-99. Review.

PMID:
12120280
13.

Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues.

de Nigris F, Cerutti J, Morelli C, Califano D, Chiariotti L, Viglietto G, Santelli G, Fusco A.

Br J Cancer. 2002 Mar 18;86(6):917-23. Erratum in: Br J Cancer 2002 Dec 2;87(12):1479.

14.

Histone deacetylases and cancer: causes and therapies.

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK.

Nat Rev Cancer. 2001 Dec;1(3):194-202. Review.

PMID:
11902574
15.

The association between telomerase activity and hormone receptor status and p53 expression in breast cancer.

Mokbel K, Ghilchik M, Williams G, Akbar N, Parris C, Newbold R.

Int J Surg Investig. 2000;1(6):509-16.

PMID:
11729859
16.

hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.

Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA.

Cell. 2001 Oct 19;107(2):149-59.

17.

Negative control of p53 by Sir2alpha promotes cell survival under stress.

Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W.

Cell. 2001 Oct 19;107(2):137-48.

18.

Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins.

Frye RA.

Biochem Biophys Res Commun. 2000 Jul 5;273(2):793-8.

PMID:
10873683
19.

Sir2 links chromatin silencing, metabolism, and aging.

Guarente L.

Genes Dev. 2000 May 1;14(9):1021-6. Review. No abstract available.

20.

Diverse and dynamic functions of the Sir silencing complex.

Guarente L.

Nat Genet. 1999 Nov;23(3):281-5. Review.

PMID:
10545947
Items per page

Supplemental Content

Support Center